Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific securities transaction.
- Transaction Type: Increase in notional interest in American Depositary Shares (ADSs).
- Instrument: ADSs (ISIN: US37733W1053).
- Transaction Date: July 14, 2016.
- Transaction Price: $43.87 per ADS.
- Total Volume: 1,250.902 ADSs.
- Context: Re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine increase in shareholding for a specific executive via dividend reinvestment.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of an insider transaction.
Important Facts for Investors to Verify
- The transaction involves Dr. M M Slaoui, Chairman of Global Vaccines.
- The increase in holdings resulted from the reinvestment of dividends, not an open market purchase.
- The transaction included both personal contributions and matching elements under the bonus plan.
- The total aggregated volume of ADSs acquired was 1,250.902.